PARIS and NEW YORK and LONDON, Feb. 28, 2026 /PRNewswire/ — AMTD Digital Inc. (“AMTD Digital” or the “Company”) (NYSE: HKD), a NYSE-listed company and a subsidiary of AMTD Group Inc., today announced the filing of its annual report on Form 20-F for the fiscal year ended October 31, 2025 with the Securities and Exchange […]
Category Archives: Pr Newswire
PARIS and NEW YORK and LONDON, Feb. 28, 2026 /PRNewswire/ — AMTD IDEA (NYSE: AMTD; SGX: HKB) subsidiary AMTD Digital Inc. (NYSE: HKD), a NYSE‑listed company and subsidiary of AMTD Group Inc., today announced it has filed its annual report on Form 20‑F with the U.S. Securities and Exchange Commission for the fiscal year ended October […]
PARIS and NEW YORK and LONDON, Feb. 28, 2026 /PRNewswire/ — AMTD Digital Inc. (“AMTD Digital” or the “Company”) (NYSE: HKD), a NYSE-listed company and a subsidiary of AMTD Group Inc., today announced the filing of its annual report on Form 20-F for the fiscal year ended October 31, 2025 with the Securities and Exchange […]
REDWOOD CITY, Calif., Feb. 28, 2026 /PRNewswire/ — Zilliz, the company behind Milvus, the world’s most widely adopted open-source vector database, today announced the general availability of Zilliz Cloud BYOC (Bring Your Own Cloud) on Microsoft Azure. With this launch, Zilliz Cloud BYOC is now available across AWS, Google Cloud Platform, and Microsoft Azure—making Zilliz the first managed vector database provider […]
Pr Newswire
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
27
Feb
Feb
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease […]
Pr Newswire
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
27
Feb
Feb
– Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder – BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted […]
Pr Newswire
Flare Therapeutics Presents Updated FX-909 Phase 1A Data in Late-Breaking Oral Presentation at 2026 ASCO Genitourinary Cancers Symposium
27
Feb
Feb
Data support emergence of differentiating clinical benefit with a favorable safety and tolerability profile for patients with advanced UC CAMBRIDGE, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) — Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced the presentation of updated clinical […]
Pr Newswire
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
27
Feb
Feb
MELBOURNE, Australia and INDIANAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry1, defining the potential prognostic value of PSMA-PET2 imaging through artificial intelligence (AI). PROMISE (PROstate cancer Molecular Imaging Standardized Evaluation)-PET is a multi-center, prospective, observational, […]
Pr Newswire
ADARx Pharmaceuticals Presents Onvuzosiran Data Supporting Potential for Sustained Attack-Free Rates with Reduced Treatment Burden in Patients with HAE
27
Feb
Feb
– Onvuzosiran achieved significant and durable reductions of plasma kallikrein levels with a favorable safety profile in Phase 1/2 – – Positive results support ongoing Phase 3 clinical trial – SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced Phase 1/2 clinical […]
Pr Newswire
SkinnyRx GLP-1 Weight Loss 2026: Compounded Semaglutide and Tirzepatide Program, Pricing, and FDA Regulatory Status Examined
27
Feb
Feb
Examining SkinnyRx’s Compounded GLP-1 Weight Loss Platform for 2026: Semaglutide and Tirzepatide Medication Formats, Subscription Pricing From $199 Per Month, 503A Pharmacy Sourcing, Clinical Research Boundaries, and What Consumers Should Verify Before Enrolling in Any Telehealth Prescription Weight Loss Program Sacramento, CA, Feb. 26, 2026 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes […]